-
Bispecific CAR T Cell Therapy Targeting BCMA and CD19 in Relapsed/Refractory Multiple Myeloma: A Phase I/II Clinical Trial
In the evolving landscape of hematology and oncology, innovative treatments for challenging conditions like relapsed or refractory multiple myeloma (R/R MM) are of paramount importance. It is in this context that the recent phase I/II, open-label study investigating the efficacy of bispecific CAR-T cell therapy targeting BCMA and CD19 comes to light, marking a significant…
-
EAU24 Expert Commentary丨Professor Tongyi Men: Bringing More Hope to Kidney Cancer Patients Through the Latest Research Advances
The situation of urological tumors in China is not optimistic, with the incidence of kidney cancer increasing annually by 4% to 7%. There is an urgent need to explore new diagnostic and therapeutic strategies to improve incidence rates and patient prognosis. The 39th Annual Congress of the European Association of Urology (EAU24) was held from…
-
2024 South-North Forum | Prof. Zhiming Shao: Breast Cancer Treatment in the Era of Precision Typing
Breast diseases have the highest incidence among women, with breast cancer being the leading malignant tumor threatening women’s health. From “one-size-fits-all” treatments to “individualized therapy” based on patients, the exploration of breast cancer treatment has been ongoing for centuries. At the 2024 South-North Forum, Prof. Zhiming Shao from Fudan University Cancer Hospital presented a report…
-
Multiparametric MRI Differentiates Small Hepatocellular Carcinoma (<3 cm) from Benign Liver Lesions Associated with Budd-Chiari Syndrome
The “International Liver Disease – Hepatic Vascular Disease Column” is an academic column initiated by Dr. Xingshun Qi from the Department of Gastroenterology at General Hospital of Northern Theater Command, in collaboration with the editorial team of International Liver Disease. This column regularly collects and organizes research progress in the field of hepatic vascular diseases,…
-
High Frequency of Type 3 Dendritic Cells in CD1c+DCs on Day 28 Post-Allo-HSCT as a Potential Marker for Severe GVHD in Pediatric Patients
llogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Chimeric Antigen Receptor T-cell (CAR-T) therapy have become crucial in the treatment of leukemia. However, the effectiveness and safety of these treatments continue to be hot topics of research. Recent breakthrough studies have provided valuable insights, particularly in the treatment of children with relapsed/refractory B-cell acute lymphoblastic leukemia…
-
2024 CSCO Guidelines Conference | Prof. Yao Zhu: Combining the Latest Research to Guide Prostate Cancer Treatment Guidelines for Patient Protection
Prostate cancer is a malignant tumor occurring in the male reproductive system. Although the incidence in China is lower than in Western countries, it has rapidly increased in recent years, now ranking as the sixth most common male malignancy. With rapid advances in related research, updating prostate cancer treatment guidelines based on the latest evidence-based…
-
La Vente de Stéroïdes: Ce que vous devez savoir
La Vente de Stéroïdes: Ce que vous devez savoir La vente de stéroïdes est un sujet controversé et souvent mal compris. Les stéroïdes, également connus sous le nom de substances…
-
2024 South-North Forum | Prof. Xiaowei Qi: Advancements in Dual Target Neoadjuvant Therapy for HER2-Positive Breast Cancer
In the first-line treatment of advanced HER2-positive breast cancer, the combination of pyrotinib and trastuzumab has introduced a new therapeutic model. The complementary mechanisms of large and small molecules have achieved a median progression-free survival (mPFS) of 24.3 months, setting a new standard for first-line treatment of advanced HER2-positive breast cancer. This combination therapy is…
Connecting Medical Expertise through Media